Shireen Mreish1, Walid Kaplan1, Fares Chedid2. 1. Division of Endocrinology, Department of Pediatric, Tawam Hospital, Al Ain, UAE. 2. Division of Neonatology, Department of Pediatric, Al Jalila Children's Specialty Hospital, Dubai, UAE.
Abstract
OBJECTIVES: The use of growth hormone (GH) in idiopathic short stature (ISS) has been a subject of debate for the past two decades. We sought to assess the effect of GH on final height (FH) in patients with ISS in our region, which has a high consanguinity rate, and compare it to the effect observed in GH deficient (GHD) patients. METHODS: We conducted a retrospective chart review from 1 January 2005 to 31 December 2013 for patients with ISS or GHD from the local United Arab Emirates population who received GH treatment and were followed-up regularly in our clinic. The change in height Z-score at 12 months and FH were assessed within each group and between the two groups. RESULTS: Twenty-one patients with ISS and 29 patients with GHD were studied. There was a significant change in height Z-score at 12 months and FH in both groups (p < 0.001). The improvement in the ISS group was comparable to the response seen in GHD patients at 12 months (0.5±0.3 standard deviation score (SDS), and 0.5±0.4 SDS, respectively; p = 0.540). The effect on FH was better in ISS group than the GHD group of all etiologies (1.3±0.6 SDS vs. 0.9±0.7 SDS, respectively; p = 0.050), there was no difference between the ISS and the subgroup of idiopathic GHD (1.3±0.5 SDS and 1.2±0.8 SDS, respectively). CONCLUSIONS: In our local population, GH has a positive effect on the short-term growth and FH of children with ISS to the same extent that has been observed in children with idiopathic GH deficiency.
OBJECTIVES: The use of growth hormone (GH) in idiopathic short stature (ISS) has been a subject of debate for the past two decades. We sought to assess the effect of GH on final height (FH) in patients with ISS in our region, which has a high consanguinity rate, and compare it to the effect observed in GH deficient (GHD) patients. METHODS: We conducted a retrospective chart review from 1 January 2005 to 31 December 2013 for patients with ISS or GHD from the local United Arab Emirates population who received GH treatment and were followed-up regularly in our clinic. The change in height Z-score at 12 months and FH were assessed within each group and between the two groups. RESULTS: Twenty-one patients with ISS and 29 patients with GHD were studied. There was a significant change in height Z-score at 12 months and FH in both groups (p < 0.001). The improvement in the ISS group was comparable to the response seen in GHD patients at 12 months (0.5±0.3 standard deviation score (SDS), and 0.5±0.4 SDS, respectively; p = 0.540). The effect on FH was better in ISS group than the GHD group of all etiologies (1.3±0.6 SDS vs. 0.9±0.7 SDS, respectively; p = 0.050), there was no difference between the ISS and the subgroup of idiopathic GHD (1.3±0.5 SDS and 1.2±0.8 SDS, respectively). CONCLUSIONS: In our local population, GH has a positive effect on the short-term growth and FH of children with ISS to the same extent that has been observed in children with idiopathic GH deficiency.
Entities:
Keywords:
Consanguinity; Growth Hormone; Growth Hormone Deficiency; Idiopathic Short Stature
Authors: Michael B Ranke; Anders Lindberg; David A Price; Feyza Darendeliler; Kerstin Albertsson-Wikland; Patrick Wilton; Edward O Reiter Journal: Horm Res Date: 2007-01-16
Authors: N J Hopwood; R L Hintz; J M Gertner; K M Attie; A J Johanson; J Baptista; J Kuntze; R M Blizzard; J F Cara; S D Chernausek Journal: J Pediatr Date: 1993-08 Impact factor: 4.406
Authors: Peter A Lee; Lars Sävendahl; Isabelle Oliver; Maithé Tauber; Oliver Blankenstein; Judith Ross; Marta Snajderova; Viatcheslav Rakov; Birgitte Tønnes Pedersen; Henrik Thybo Christesen Journal: Int J Pediatr Endocrinol Date: 2012-07-12